APVO · Aptevo Therapeutics Inc.

This 8-K filing conveys a high-materiality inflection point for Aptevo, anchored by compelling clinical validation, leadership stabilization, and strengthened financial capacity. The RAINIER trial data for mipletamig — particularly the 81% CR/CRi rate and absence of CRS in frontline AML — directly addresses two critical investor concerns: efficacy durability and safety tolerability relative to existing venetoclax-based regimens. The comparison to VIALE-A’s 66.4% CR/CRi and 37% CR rates is not merely contextual but signals potential clinical superiority in a high-unmet-need population, reinforcing orphan drug designation value and regulatory leverage. Leadership continuity is operationally significant: Lamothe’s appointment as CEO and White’s move to Executive Chair formalize a governance structure designed for focused execution across clinical, regulatory, and capital strategy — especially vital ahead of year-end Phase 2 dose selection and potential pivotal trial design decisions. Financially, the $60 million SEPA is materially distinct from the $0.9 million raised under prior agreements; it extends capital optionality through 2029, decoupling near-term execution from immediate dilution pressure and enabling measured advancement of both mipletamig and trispecific candidates. While the $14.5 million cash balance alone would cover only limited runway, the new facility transforms liquidity into strategic flexibility — allowing Aptevo to prioritize data generation over fundraising timing. Collectively, these disclosures shift investor focus from survival risk to value inflection, with clinical de-risking now paired with operational and financial enablers for milestone progression.